
ORKA Stock Forecast & Price Target
ORKA Analyst Ratings
Bulls say
Oruka Therapeutics is a clinical-stage biopharmaceutical company with a diverse pipeline of monoclonal antibody therapeutics targeting inflammatory and immunological indications, with a primary focus on psoriasis and related conditions. The recent expanded license agreement for its lead program, ORKA-001, provides additional potential for commercial opportunities in the future. ORKA-001 has demonstrated best-in-class efficacy in PsO, and its extended half-life and potential for once-yearly maintenance dosing set it apart from other competitors in the market. With ongoing trials and promising data, Oruka has the potential to become a leader in the IL-23 inhibitor space and attract interest from potential partners or acquirers. Overall, the company has a strong foundation for continued growth and success in the coming years.
Bears say
Oruka Therapeutics is facing financial struggles, as shown by their 1Q26 net loss of $0.48 per share and the need to conduct an upsized equity offering. Additionally, the expected data from the EVERLAST-B trial is not anticipated until 2027, indicating a slow timeline for potential revenue. Furthermore, competition in the psoriasis treatment market is high, with established drugs such as Skyrizi already in the market.
This aggregate rating is based on analysts' research of Oruka Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ORKA Analyst Forecast & Price Prediction
Start investing in ORKA
Order type
Buy in
Order amount
Est. shares
0 shares